Navigation Links
invivodata Announces ePROficiency 2009 Web Seminar Series
Date:6/9/2009

Five Complimentary Webinars to Showcase Case Studies and Patient Reported Outcome Strategies

PITTSBURGH, June 9 /PRNewswire/ -- invivodata inc., the industry leader in electronic patient reported outcomes (ePRO) solutions and services for global clinical research, today announced its 2009 ePROficiency(TM) Web seminar series on Patient Reported Outcomes (PRO).

The webinar series is a continuation of invivodata's educational initiative which focuses on recent regulatory and industry trends related to PROs. Each of the series' five webinars is derived from presentations that were delivered by industry experts during invivodata's recently concluded ePROficiency Conference in Naples, FL.

Each complimentary webinar will feature international pharmaceutical researchers delivering insight on specific aspects of PRO in clinical research and answering questions on topics including:

  • Improving Measure Sensitivity in Early Stage Research - June 18
  • A Conceptual Model in the Context of a Global Drug Development Program - July 30
  • Developing PROs: Common Pitfalls & Recent Experiences - September 10
  • Supporting Regulatory Submissions and Inspections: the ePRO Perspective - October 22
  • eDiaries: From Clinical Proof-of-Concept through to NDA Approval - December 3

"We've always been very pleased with the response to our webinar programs, which represents the growing interest we've seen in PROs for clinical research," said Dr. Jean Paty, chief scientist and regulatory advisor at invivodata's consulting division, PRO Consulting(R). Considering the evolving use of PROs and its regulatory implications, it's no surprise that so many global trial sponsors are eager to learn more about the latest PRO strategies and trends."

To register for any of the webinars or to see a complete schedule of upcoming invivodata events, please visit http://www.invivodata.com/eweb/.

About invivodata inc.

invivodata combines behavioral science, information technology, and clinical research expertise to capture high quality clinical trial data directly from patients. invivodata's electronic Patient Reported Outcomes (ePRO) solutions, which are based on over 20 years of research, deliver reliable patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague paper-based self-report data. invivodata's solutions include comprehensive trial-support services that facilitate the collection of ePRO data, web-based access to study data and operational reports that give researchers and sponsors visibility into study progress, and scientific and regulatory consulting on the use of PRO data in a regulated environment. invivodata's solution has been used in more than 275 clinical programs and is the industry-leading ePRO system in delivering primary efficacy data for FDA drug approvals. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters is in London, England; and its technology development center is in Scotts Valley, Calif., USA. For more information visit www.invivodata.com.

    For more information, contact:

    invivodata inc.
    Christine Tobin
    Corporate Communications Specialist
    (412) 390-3000, ext. 3502
    ctobin@invivodata.com


'/>"/>
SOURCE invivodata inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. invivodata and PRO Consulting to Present at International Industry Events
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Surgical Wound Market with the addition of its newest module, US Hemostats & ... market for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants ...
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... INDIANAPOLIS , Oct. 11, 2017  VMS BioMarketing, a ... of a nationwide oncology Clinical Nurse Educator (CNE) network, which ... growing need for communication among health care professionals to enhance ... physicians, nurses, office staff, and other health care professionals to ... for breast cancer. ...
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
Breaking Biology News(10 mins):